Back to News
AI
Artificial Intelligence-Enabled Pharmacovigilance for Neuropsychiatric Therapies: Advancing U.S. Drug Safety Surveillance and Regulatory Decision-Making - Cureus
cureus.com·October 13, 2026·1 min read
AI Summary
AI-powered pharmacovigilance systems are being developed to enhance monitoring of safety signals for neuropsychiatric medications in the United States. These advanced surveillance tools aim to improve regulatory decision-making by enabling faster detection and analysis of adverse events associated with mental health therapies.
From the source
Artificial Intelligence-Enabled Pharmacovigilance for Neuropsychiatric Therapies: Advancing U.S. Drug Safety Surveillance and Regulatory Decision-Making Cureus
The full text couldn't be loaded here (the source may require a subscription).
View original at cureus.comKeep reading
An OpenAI Employee Allegedly Used a Chatbot to Help Plant a Recording Device at the OfficeWired — AI · 1h agoChallenge is not AI, but rethinking business models, says expertcnnbrasil.com.br · 1h agoScience Corporation implants its vision-restoring chip in its first Stargardt disease patientTechCrunch AI · 1h agoK-Beauty Gets AI Makeover with Virtual Experience Spaces in Seoul's Hongdae and Busan's Seomyeonkookje.co.kr · 1h ago
Was this useful?